Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study analyzed reports from the FDA Adverse Event Reporting System and observed an upward trend in suicidality-related safety signals among young male finasteride users since 2019, peaking in 2022, highlighting emerging psychiatric safety concerns and the need for vigilant monitoring of this population.

This review explores the potential of metal nanoparticles as innovative treatments for alopecia, highlighting their effectiveness in promoting hair regrowth, enhancing drug delivery, and modulating gene expression while also assessing the related experimental methodologies and regulatory considerations.

This review assessed the safety of oral antiandrogen treatments for female androgenetic alopecia, finding spironolactone to be potentially safe even in high-risk populations, but indicated ongoing uncertainty regarding other medications, especially for patients with a history of gynecologic cancers.

This study analyzed the professional backgrounds of 4,405 aesthetic practitioners in the UK, revealing that 32% are doctors, 24% are dentists, and 13% are nurses, with significant representation from plastic surgery and dermatology among specialists.

This article summarizes the MHRA report on finasteride and does not present new clinical findings.

The MHRA announced on 11 May 2026 that it will update the product information for finasteride and dutasteride to include more details on potential psychiatric and sexual side effects, following a review of existing evidence.

This study surveyed UK patients who experienced adverse events from Botulinum Toxin for cosmetic purposes, finding 79% reported issues like long-lasting anxiety, and highlighting low awareness of regulatory bodies and reporting structures.

Finasteride may cause depression, suicidal thoughts, and sexual side effects.

Finasteride (Propecia) may cause depression and suicidal thoughts; stop use and inform a healthcare professional if symptoms develop.

Finasteride can cause depression, suicidal thoughts, and lasting psychiatric and sexual issues.

This article discusses a serious side effect associated with a potentially widely used cosmetic product but reports no new experimental results.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

In this report, the European Medicines Agency confirmed in 2025 that finasteride, a drug used to treat hair loss in men, is linked to suicidal thoughts, a concern previously raised by patient advocacy groups.

In this study, researchers created the WRAHPS Guidelines to standardize the reporting of preclinical wound healing studies, aiming to improve transparency, enable comparative analysis, and support the development of human clinical trials for wound healing disorders.

This article describes the Australian Medicines Handbook as a compact, readable, and comprehensive drug reference guide for Australian practitioners, but it does not present new research findings.

This study evaluated the quality of androgenetic alopecia guidelines using the AGREE II instrument and found the European guideline to be the highest-rated, while American guidelines required modifications.

This study found that a human relevant potency threshold for estrogen receptor alpha agonism may serve as a health-protective screening tool, and highlights inference performance as essential for scientific confidence frameworks.

In this critique, the authors argue that the American College of Physicians' recent guideline for migraine preventive therapy is based on a flawed analysis with low confidence levels and outdated data, failing to acknowledge newer migraine-specific therapies with stronger evidence and better tolerability.

This article provides a guideline for physicians on managing hair disorders, including recent developments and clinical practice guidelines, but it reports no new research findings.

This guideline summary, endorsed by six Spanish pediatric societies, outlines consensus recommendations for managing childhood asthma, emphasizing diagnosis, maintenance treatment with low-dose inhaled corticosteroids, and patient education for effective control.

This article reviews current guidelines for managing androgenetic alopecia and highlights the need for guidelines tailored to Japan; it reports no new clinical results.

This article provides diagnosis and treatment guidelines for hyperandrogenic disorders in women but reports no new clinical results; it offers a summary of accepted scientific information and suggestions for clinical practice.

This article outlines diagnosis and treatment guidelines for androgenetic alopecia but reports no new clinical findings.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

This article updates Japanese guidelines for diagnosing and treating male and female-pattern hair loss, recommending specific drugs and therapies while advising against certain treatments for female-pattern hair loss.

This article discusses the perceived shortcomings of nineteenth-century British drama in addressing contemporary ideas, questioning its literary vitality beyond stage performance, and reports no new results.

This study identified melanoma, squamous cell carcinoma, basal cell carcinoma, psoriasis, and atopic dermatitis as top priority topics for dermatological clinical practice guideline development in the Netherlands.

In this study, most surveyed physicians were aware of the meningioma risk linked to cyproterone acetate monotherapy, but many did not recall receiving updated safety communications.

This review discusses a new multidisciplinary guideline for treating male hypogonadism and emphasizes a comprehensive approach but reports no new experimental results.